Elizabeth Yusupov
Optometrist · Bronx, NYNPI 1437502911
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 90.0% of the total across 138 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 23 manufacturers, the largest accounting for just 15.5% — the pattern of someone who eats at a lot of different presentations. Among optometrist clinicians in NY with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 138 payments — averaging $71.63 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Johnson & Johnson Vision Care, Inc.$2K
- Harrow Eye, LLC$2K
- AbbVie$1K
- Eyevance Pharmaceuticals LLC$1K
- Biotissue Holdings Inc.$585
- Amgen$519
- plus $3K from 17 others
What the payments were for
- Travel & lodging$96610%
- Food & beverage$8,89990%
- Gifts$190%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Johnson & Johnson Vision Care, Inc. | 10 | $1,533 |
| Harrow Eye, LLC | 25 | $1,516 |
| AbbVie(2 entities) | 23 | $1,234 |
| Eyevance Pharmaceuticals LLC | 9 | $1,206 |
| Biotissue Holdings Inc. | 10 | $585 |
| Amgen | 5 | $519 |
| Glaukos Corporation | 4 | $515 |
| Tarsus Pharmaceuticals, Inc. | 13 | $511 |
| Bausch & Lomb Americas Inc. | 4 | $445 |
| Dompe US, Inc. | 5 | $386 |
| Alcon | 3 | $316 |
| Novartis | 9 | $313 |
| Coopervision Inc. | 3 | $199 |
| Bausch & Lomb, A Division Of Bausch Health US, LLC | 2 | $150 |
| Rxsight Inc | 1 | $147 |
| Biogen | 1 | $90 |
| Oyster Point Pharma, Inc. | 2 | $54 |
| Aerie Pharmaceuticals, Inc. | 2 | $40 |
| Visioneering Technologies, Inc. | 2 | $31 |
| Sun Pharmaceutical Industries Inc. | 2 | $30 |
| Synergeyes, Inc. | 1 | $25 |
| Thea Pharma Inc. | 1 | $20 |
| Carl Zeiss Meditec AG | 1 | $19 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Acuvue$1,381
- VEVYE$610
- Photrexa$515
- TEPEZZA$500
- Tobradex ST$476
- Prokera$459
- Zerviate$396
- MIEBO$396
- XDEMVY$389
- KXL System$364
- XIIDRA$349
- AmnioGraft$336
- Rocklatan$291
- VUITY$254
- RESTASIS$248
- Oxervate$244
- RESTASIS MULTIDOSE$240
- Flarex$165
- iStent inject Trabecular Micro-Bypass Stent System$151
- Rhopressa$148
How this compares
$9,885 in reported general payments places this provider in the 95th percentile of 2,743 optometrist providers in New York.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| RestasisCyclosporine | 42 | $35,735 |
| XiidraLifitegrast | 23 | $17,672 |
| LumiganBimatoprost | 26 | $12,091 |
| CombiganBrimonidine Tartrate/Timolol | 19 | $6,749 |
| RocklatanNetarsudil Mesylat/Latanoprost | 18 | $6,589 |
| Brimonidine Tartrate-TimololBrimonidine Tartrate/Timolol | 19 | $3,301 |
| Prednisolone Acetate | 32 | $1,842 |
| Latanoprost | 101 | $1,003 |
| Azelastine Hcl | 34 | $972 |
| Dorzolamide Hcl | 33 | $531 |
| Ketorolac Tromethamine | 19 | $524 |
| Dorzolamide-TimololDorzolamide Hcl/Timolol Maleat | 28 | $385 |
| Timolol Maleate | 20 | $316 |
| Brimonidine Tartrate | 17 | $227 |
| Ofloxacin | 14 | $200 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AbbVieRestasis, Lumigan, Combigan | $1,234 | $54,57587 claims |
| Bausch & Lomb Americas Inc.Xiidra | $445 | $17,67223 claims |
| Aerie Pharmaceuticals, Inc.Rocklatan | $40 | $6,58918 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 2,743 optometrist providers in New York.
Other optometrist in Bronx
- Evan KaplanBronx$19K
- David GarciaBronx$10K
- Katari CampbellBronx$10K
- Albert ContentoBronx$10K
- Peter BaeBronx$8K
- Roy KlineLake Katrine$822K
- Susan ResnickNew York$463K
- Murray FingeretHewlett$374K
- Albert MorierSlingerlands$347K
- Denise WhittamNew York$343K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.